Trends and Disparities in Treatment Utilization for Early-Stage Hepatocellular Carcinoma in the Veteran Population.
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
received:
22
11
2021
accepted:
28
04
2022
pubmed:
23
5
2022
medline:
11
8
2022
entrez:
22
5
2022
Statut:
ppublish
Résumé
The incidence of hepatocellular carcinoma (HCC) has substantially increased over the last two decades within the Veteran Affairs Health System (VAHS). This study aims to describe the temporal trend of early-stage HCC (ES-HCC) treatment in the VAHS and identify patient/hospital factors associated with treatment disparities. VA Corporate Data Warehouse was used to identify patients diagnosed with ES-HCC (stages I/II) from 2001 to 2015. Initial course of therapy was categorized as curative treatment (CT), noncurative treatment (NCT), or no treatment (NT). Univariate logistic regression and stepwise multivariate logistic regression models were used to analyze factors associated with receipt of treatment (CT/NCT) versus NT and receipt of CT versus NCT. Our study included 9504 patients (15% CT, 51% NCT, and 34% NT). During the study period, the rate of overall treatment increased, while the rate of CT decreased (p < 0.001). Stage II, age > 65 years, presence of non-alcoholic fatty liver disease (NAFLD), Child-Pugh C, higher Model for End-Stage Liver Disease (MELD) score, platelets < 100,000/mm There is a significant trend toward increased overall treatment utilization with decreased use of curative-intent approaches for ES-HCC in the national veteran population, and significant hospital and regional disparities exist. Further characterization and investigation of these factors may facilitate implementation of interventions to improve treatment utilization for the veteran population with HCC.
Sections du résumé
BACKGROUND
BACKGROUND
The incidence of hepatocellular carcinoma (HCC) has substantially increased over the last two decades within the Veteran Affairs Health System (VAHS). This study aims to describe the temporal trend of early-stage HCC (ES-HCC) treatment in the VAHS and identify patient/hospital factors associated with treatment disparities.
PATIENTS AND METHODS
METHODS
VA Corporate Data Warehouse was used to identify patients diagnosed with ES-HCC (stages I/II) from 2001 to 2015. Initial course of therapy was categorized as curative treatment (CT), noncurative treatment (NCT), or no treatment (NT). Univariate logistic regression and stepwise multivariate logistic regression models were used to analyze factors associated with receipt of treatment (CT/NCT) versus NT and receipt of CT versus NCT.
RESULTS
RESULTS
Our study included 9504 patients (15% CT, 51% NCT, and 34% NT). During the study period, the rate of overall treatment increased, while the rate of CT decreased (p < 0.001). Stage II, age > 65 years, presence of non-alcoholic fatty liver disease (NAFLD), Child-Pugh C, higher Model for End-Stage Liver Disease (MELD) score, platelets < 100,000/mm
CONCLUSIONS
CONCLUSIONS
There is a significant trend toward increased overall treatment utilization with decreased use of curative-intent approaches for ES-HCC in the national veteran population, and significant hospital and regional disparities exist. Further characterization and investigation of these factors may facilitate implementation of interventions to improve treatment utilization for the veteran population with HCC.
Identifiants
pubmed: 35599285
doi: 10.1245/s10434-022-11897-3
pii: 10.1245/s10434-022-11897-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5488-5497Informations de copyright
© 2022. Society of Surgical Oncology.
Références
Bray F, Ferlay J, Soerjomataram I. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. 2018;394-424. https://doi.org/10.3322/caac.21492
Outcomes M. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level results from the global burden of disease study 2015. JAMA Oncol. 2017;98121(12):1683–91. https://doi.org/10.1001/jamaoncol.2017.3055 .
doi: 10.1001/jamaoncol.2017.3055
Beste LA, Leipertz SL, Green PK, Dominitz JA, Ross D, Ioannou GN. Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US veterans, 2001–2013. Gastroenterology. 2015;149(6):1471-1482.e5. https://doi.org/10.1053/j.gastro.2015.07.056 .
doi: 10.1053/j.gastro.2015.07.056
pubmed: 26255044
Mittal S, El-Serag HB, Sada YH, et al. Hepatocellular carcinoma in the absence of cirrhosis in United States veterans is associated with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2016;14(1):124-131.e1. https://doi.org/10.1016/j.cgh.2015.07.019 .
doi: 10.1016/j.cgh.2015.07.019
pubmed: 26196445
Mittal S, Sada YH, El-Serag HB, et al. Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population. Clin Gastroenterol Hepatol. 2015. https://doi.org/10.1016/j.cgh.2014.08.013 .
doi: 10.1016/j.cgh.2014.08.013
pubmed: 26196445
pmcid: 4690789
Fisher ES, Welch HG. The future of the department of veterans affairs health care system. JAMA. 1995. https://doi.org/10.1001/jama.1995.03520320061042 .
doi: 10.1001/jama.1995.03520320061042
pubmed: 7563457
Serper M, Kaplan DE, Serper M, et al. Association of provider specialty and multidisciplinary care with hepatocellular carcinoma treatment and mortality. Gastroenterology. 2017. https://doi.org/10.1053/j.gastro.2017.02.040 .
doi: 10.1053/j.gastro.2017.02.040
pubmed: 28283421
Huerta S, Pham T, Foster S, Livingston EH, Dineen S. Outcomes of emergent inguinal hernia repair in veteran octogenarians. Am Surg. 2014. https://doi.org/10.1177/000313481408000519 .
doi: 10.1177/000313481408000519
pubmed: 24887727
Rodriguez Villalvazo Y, McDanel JS, Beste LA, Sanchez AJ, Vaughan-Sarrazin M, Katz DA. Effect of travel distance and rurality of residence on initial surveillance for hepatocellular carcinoma in VA primary care patient with cirrhosis. Health Serv Res. 2020. https://doi.org/10.1111/1475-6773.13241 .
doi: 10.1111/1475-6773.13241
pubmed: 31763691
Davila JA, Kramer JR, Duan Z, et al. Referral and receipt of treatment for hepatocellular carcinoma in United States veterans: effect of patient and nonpatient factors. Hepatology. 2013;57(5):1858–68. https://doi.org/10.1002/hep.26287 .
doi: 10.1002/hep.26287
pubmed: 23359313
Zou WY, El-Serag HB, Sada YH, et al. Determinants and outcomes of hospice utilization among patients with advance-staged hepatocellular carcinoma in a Veteran affairs population. Dig Dis Sci. 2018. https://doi.org/10.1007/s10620-018-4989-4 .
doi: 10.1007/s10620-018-4989-4
pubmed: 30560329
pmcid: 6010049
Fihn SD, Francis J, Clancy C, et al. Insights from advanced analytics at the veterans health administration. Health Aff. 2014. https://doi.org/10.1377/hlthaff.2014.0054 .
doi: 10.1377/hlthaff.2014.0054
Health Services Research and Development. Corporate Data Warehouse. US Department of Veterans Affairs.
Quan H, Fong A, Burnand B, Saunders LD, Feasby TE, Ghali WA. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005. https://doi.org/10.1016/j.aquaculture.2009.07.004 .
doi: 10.1016/j.aquaculture.2009.07.004
pubmed: 16224307
Kaplan DE, Dai F, Aytaman A, et al. Development and performance of an algorithm to estimate the Child–Turcotte–Pugh score from a national electronic healthcare database. Clin Gastroenterol Hepatol. 2015;13(13):2333-2341.e6. https://doi.org/10.1016/j.cgh.2015.07.010 .
doi: 10.1016/j.cgh.2015.07.010
pubmed: 26188137
pmcid: 4655141
Kamath PS, Kim WR. The model for end-stage liver disease (MELD). Hepatology. 2007;45(3):797–805. https://doi.org/10.1002/hep.21563 .
doi: 10.1002/hep.21563
pubmed: 17326206
Trombold J, Farmer RW, McCafferty M. The impact of colorectal cancer screening in a Veteran Hospital population. Am Surg. 2013. https://doi.org/10.1177/000313481307900330 .
doi: 10.1177/000313481307900330
pubmed: 23461957
N. T, P. R, D.L. W, et al. Evaluating screening approaches for hepatocellular carcinoma in a cohort of HCV related cirrhosis patients from the Veteran’s Affairs Health Care System. BMC Med Res Methodol. 2018. https://doi.org/10.1186/s12874-017-0458-6 LK - http://ucelinks.cdlib.org:8888/sfx_local?sid=&genre=&issn=&date=2018&volume=18&issue=1&spage=1&epage=&title=BMC+medical+research+methodology&atitle=Evaluating+screening+approaches+for+hepatocellular+carcinoma+in+a+cohort+of+HCV+related+cirrhosis+patients+from+the+Veteran%27s+Affairs+Health+Care+System&aulast=Tayob&aufirst=Nabihah&isbn=&id=DOI:10.1186%2Fs12874-017-0458-6&ABBR=&arnumber=&sid=EMBASE&issn=14712288&id=doi:10.1186%2Fs12874-017-0458-6&atitle=Evaluating+s
Tayob N, Christie I, Richardson P, et al. Validation of the hepatocellular carcinoma early detection screening (HES) algorithm in a cohort of veterans with cirrhosis. Clin Gastroenterol Hepatol. 2019. https://doi.org/10.1016/j.cgh.2018.12.005 .
doi: 10.1016/j.cgh.2018.12.005
pubmed: 30557738
Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018. https://doi.org/10.1002/hep.29086 .
doi: 10.1002/hep.29086
pubmed: 29624699
Vitale A, Morales RR, Zanus G, et al. Barcelona clinic liver cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study. Lancet Oncol. 2011. https://doi.org/10.1016/S1470-2045(11)70144-9 .
doi: 10.1016/S1470-2045(11)70144-9
pubmed: 21684210
Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 2016. https://doi.org/10.1053/j.gastro.2015.12.041 .
doi: 10.1053/j.gastro.2015.12.041
pubmed: 26795574
Shah SA, Smith JK, Li YF, Ng SC, Carroll JE, Tseng JF. Underutilization of therapy for hepatocellular carcinoma in the medicare population. Cancer. 2011;117(5):1019–26. https://doi.org/10.1002/cncr.25683 .
doi: 10.1002/cncr.25683
pubmed: 20945363
Hoehn RS, Hanseman DJ, Jernigan PL, Wima K, Ertel AE, Abbott DE, Shah SA. Cincinnati research in outcomes and safety in surgery (CROSS). Disparities in care for patients with curable hepatocellular carcinoma. HPB (Oxford). 2015;17(9):747–52. https://doi.org/10.1111/hpb.12427 .
doi: 10.1111/hpb.12427
pubmed: 26278321
pmcid: 4557647
Yopp AC, Mansour JC, Beg MS, et al. Establishment of a multidisciplinary hepatocellular carcinoma clinic is associated with improved clinical outcome. Ann Surg Oncol. 2014. https://doi.org/10.1245/s10434-013-3413-8 .
doi: 10.1245/s10434-013-3413-8
pubmed: 25074660
Chang TT, Sawhney R, Monto A, Davoren JBEN. Implementation of a multidisciplinary treatment team for hepatocellular cancer at a Veterans Affairs Medical Center improves survival. 2008. https://doi.org/10.1080/13651820802356572
Lau K, Salami A, Barden G, et al. The effect of a regional hepatopancreaticobiliary surgical program on clinical volume, quality of cancer care, and outcomes in the veterans affairs system. JAMA Surg. 2014. https://doi.org/10.1001/jamasurg.2014.1711 .
doi: 10.1001/jamasurg.2014.1711
pubmed: 25207711
Goldberg DS, Taddei TH, Serper M, et al. Identifying barriers to hepatocellular carcinoma surveillance in a national sample of patients with cirrhosis. Hepatology. 2017. https://doi.org/10.1002/hep.28765 .
doi: 10.1002/hep.28765
pubmed: 28777874
Singal AG, Yopp AS, Skinner C, Packer M, Lee WM, Tiro JA. Utilization of hepatocellular carcinoma surveillance among American patients: a systematic review. J Gen Intern Med. 2012. https://doi.org/10.1007/s11606-011-1952-x .
doi: 10.1007/s11606-011-1952-x
pubmed: 22215266
pmcid: 3378733
Hwa KJ, Dua MM, Wren SM, Visser BC. Missing the obvious: psychosocial obstacles in veterans with hepatocellular carcinoma. HPB. 2015. https://doi.org/10.1111/hpb.12508 .
doi: 10.1111/hpb.12508
pubmed: 26374349
pmcid: 4644365
Shiina S, et al. Percutaneous ablation for hepatocellular carcinoma: comparison of various ablation techniques and surgery. Can J Gastroenterol Hepatol, 2018. 2018.
Putzer D, et al. Thermal ablation—an option in curative treatment of HCC. Memo Mag Eur Med Oncol. 2020;13(2):207–11.
Zhu F, Rhim H. Thermal ablation for hepatocellular carcinoma: what’s new in 2019. Chin Clin Oncol. 2019;8(6):58–58.
doi: 10.21037/cco.2019.11.03
O’Leary C, Mahler M, Soulen MC. Curative-intent therapies in localized hepatocellular carcinoma. Curr Treat Options Oncol. 2020;21(4):1–14.
doi: 10.1007/s11864-020-0725-3